A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer Extensive Stage Intervention: Drug: Carboplatin + Paclitaxel + Durvalumab Sponsor: Intergroupe Francophone de Cancerologie Thoracique Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Research | Small Cell Lung Cancer | Study